Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
EBOS Group (EBO) / HY26

Cash conversion collapsed to 15.4% as working capital absorbed $348m

Revenue grew 13.0% and FY26 EBITDA guidance was reaffirmed, but operating cash flow fell to $46.6m and the dividend was not covered by free cash flow.

Healthcare / Healthcare distribution

EBO revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY26 was $6.8b, versus $12.3b in FY25.

EBO EBITDA margin

EBITDA margin across covered periods.

↗
Loading chart...
HY26 was 4.5%, versus 4.5% in FY25.

EBO operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY26 was $46.6m, versus $418.5m in FY25.

EBO working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
HY26 was $348m, versus $97.4m in FY25.
Release date
25 February 2026
Published
21 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

HY26 vs HY25

Revenue

$6.8b

+13.0% ↑ vs $6b

EBITDA

$302.7m

+9.7% ↑ vs $275.8m

Net profit after tax

$124.8m

+12.9% ↑ vs $110.5m

Net cash inflow from operating activities

$46.6m

-75.5% ↓ vs $189.8m

Interim dividend per share

57.0c

flat vs 57.0c

Total assets

$7.6b

+10.9% ↑ vs $6.8b

What changed

Operating cash flow fell to $46.6m from $189.8m in HY25, a 75.5% decline that pulled cash conversion (OCF/EBITDA) down to 15.4% from 68.8%

Free cash flow was negative $24.0m, while working capital absorbed roughly $348m, with trade debtors up 17.3% to $1.7b against revenue growth of 13.0%.

Revenue rose 13.0% to $6.8b and reported EBITDA rose 9.7% to $302.7m. Profit before tax grew 4.4% to $162.7m, while NPAT grew 12.9% to $124.8m, lifted by a fall in the effective tax rate to 22.2% from 28.3%. The interim dividend was held at 57.0 cps.

Gross borrowings rose to $1.4b and net debt to $1.1b, but net debt/EBITDA edged down to 3.7x from 3.9x on the trailing earnings base.

What matters

Cash quality has materially deteriorated

OCF/EBITDA of 15.4% versus 68.8% a year ago, and FCF of -$24.0m, mean reported earnings were not converted into cash this half. This matters because the maintained dividend of 57.0 cps was 93.3% of NPAT but -485.2% of pre-lease FCF, so capital returns this half were funded from the balance sheet rather than from operating performance.

The headline NPAT is tax-flattered; PBT is the cleaner read. PBT grew 4.4% while NPAT grew 12.9%, an 8.5 percentage-point gap driven by the effective tax rate dropping 6.1pp. Operating earnings are growing well below the rate the bottom line implies, and the 4.4% PBT growth sits well below the 13.0% revenue line.

Working capital is the swing factor. Receivable days rose to 45.0 from 43.3 and operating working capital expanded by around $348m, more than the entire prior-year half's OCF. Unless this unwinds in H2, leverage discipline and dividend cover both depend on it.

Expectations

Management has reaffirmed FY26 EBITDA guidance and signalled confidence in an H2 uplift driven by productivity and utilisation of strategic investments

The supplied seasonal pattern shows HY25 delivered 48.8% of FY25 revenue, 49.6% of EBITDA and 51.4% of NPAT, and operating cash flow was historically more H2-weighted (HY25 represented 45.4% of FY25 OCF). That shape is consistent with management's H2 framing on earnings, but it does not by itself rescue the cash gap.

Underlying EBITDA was disclosed at $300m, up 3.2% — well below the 9.7% reported EBITDA growth — which sets a more modest organic baseline against which the reaffirmed guidance and "H2 uplift" claim should be judged.

Quality of result

The result is lower quality than the headlines suggest

NPAT growth of 12.9% reflects a step-down in the effective tax rate to 22.2%, not operating leverage; on the cleaner PBT basis growth was 4.4%, less than a third of revenue growth. Reported EBITDA grew 9.7% but Underlying EBITDA grew only 3.2%, indicating non-underlying items are a meaningful contributor to the reported growth rate.

On the cash side, capex rose 26.7% to $70.6m (1.0% of revenue), but the dominant pressure was working capital. With OCF of $46.6m against EBITDA of $302.7m, around $256m of EBITDA did not arrive as operating cash this half. Whether this is timing-driven (debtor build into period-end, seasonal stocking) or a structural step-up in working capital intensity is the central durability question for the result.

Unresolved

Open questions

What specifically drove the $348m working capital absorption, and how much is expected to reverse in H2 FY26?
Why did the effective tax rate fall to 22.2% from 28.3%, and is this a sustainable run-rate?
Why does Underlying EBITDA growth of 3.2% diverge so sharply from reported EBITDA growth of 9.7%?
How is the maintained 57.0 cps interim dividend being funded given FCF of -$24.0m, and what is the policy if cash conversion does not normalise?
What concrete productivity and utilisation milestones underpin the reaffirmed FY26 EBITDA guidance and the H2 uplift confidence?

This briefing cannot assess customer-level receivables ageing, the split of the working capital build between volume, mix and timing, or any segment-level cash conversion behind the group OCF figure.

Chat

Ask about EBO HY26

Ask follow-up questions about EBOS Group's HY26 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about EBO HY26

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about EBOS Group's HY26 result.

What specifically drove the $348m working capital absorption, and how much is expected to reverse in H2 FY26?Why does "Cash quality has materially deteriorated" matter?How strong was the cash and earnings quality in HY26?What should I watch next for EBO after HY26?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Interim Report

HY26 / financial report↗

Investor Presentation

HY26 / results presentation↗

Media Release

HY26 / media release↗

NZX Results Announcement

HY26 / results announcement↗

Prior comparable period

Interim Report

HY25 / financial report↗

Media Release

HY25 / media release↗

NZX Results Announcement

HY25 / results announcement↗

Full-year context

Annual Report

FY25 / financial report↗

Media Release

FY25 / media release↗

NZX Results Announcement

FY25 / results announcement↗

Release context

Annual Meeting Presentations

HY26 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Cash conversion quality

This result converted 15.4% of EBITDA to operating cash flow, -53.5pp versus the prior comparable period.

→

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 8.5pp, with a distortion flag in the result.

→

Leverage and balance-sheet risk

Net debt / EBITDA is 3.70x, -0.16x versus the prior comparable period.

→

Dividend coverage and payout pressure

Dividend payout versus NPAT is 93.3%.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when EBO publishes next

Get the next EBOS Group briefing and related NZX reporting-season updates by email.